News

Switzerland is often perceived as a “small market” – which sometimes leads to one of two extremes: being deprioritised, or being overengineered from day one. Based on our experience, successful rare disease launches in Switzerland are not about size or complexity, but about making the right decisions at the right time. A smart entry to the Swiss market takes a holistic view and considers: Swissmedic regulatory requirements market access pathways and reimbursement strategy lea

Switzerland is not part of the EU, and its pathway for orphan drug designation (ODD) comes with relevant differences that can be of significantly benefit biotech and pharma companies. Key differences in the ODD pathway (simplified) In the EU, if another orphan drug already exists for the same indication, a “significant benefit” over existing therapies must be demonstrated. In Switzerland, this requirement does not apply. The only requirement for an ODD in Switzerland is a pre

From defining your European strategy to attracting top talent and navigating complex regulatory environments, Jesse covers it all...

Over the last 4.5 years, we’ve had the privilege of working with innovative biotech and pharma companies, guiding them through market entry, market access and commercialization strategies to bring their breakthrough products to Switzerland. We are immensely grateful for the trust our clients place in us and for the opportunity to contribute to advances in healthcare. Our commitment remains unwavering: to deliver strategic insights that ensure our clients’ success and broaden

At Swizzard Pharma, we provide hands-on market access services tailored to your product and the Swiss healthcare system.

Switzerland’s reputation for scientific excellence, a stable economy, and robust healthcare infrastructure has long made it a prime...